Flex Pharma (NASDAQ: FLKS) shares are up 23% this morning on news that the company’s co-activator of TRPA1 and TRPV1, FLX-787, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to treat severe muscle cramps in patients with ALS. Currently, no treatments for this condition are approved in the U.S. “With Phase 2 clinical trials in both ALS and CMT expected to initiate this quarter in the US, FLX-787 will be amongst the most advanced, novel compounds in the clinic for these degenerative neurological diseases. The R&D team is focused on the execution of these new Phase 2 IND studies, as well as completion of the ongoing exploratory Phase 2 spasticity study in MS in Australia. These studies are expected to yield several important data readouts in 2018,” Flex Pharma interim president and CEO William McVicar, Ph.D. stated in the news release.
To view the full press release, visit: http://nnw.fm/jsiO4
About Flex Pharma
Flex Pharma, Inc. is a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with the severe neurological diseases of ALS, MS and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chair Christoph Westphal, M.D., Ph.D. For more information, visit www.flex-pharma.com.
More from NetworkNewsBreaks
ORHub, Inc. (ORHB) Announces Launch of Neurosurgery Service Line
Eltek (NASDAQ: ELTK) Shares Swell on $3M Order by Governmental Authority
About NetworkNewsBreaks
NetworkNewsBreaks (NNB) is a division of NetworkNewsWire (NNW) focused on providing rapid summaries of corporate news that caught the attention of the NNW team. NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
